Announced by researchers at a cancer conference in Chicago, the new findings show earlier and combined use of existing treatments can have a significant impact on advanced disease, but questions remain about its suitability for all men.
New research funded by Prostate Cancer UK has discovered a blood test that can predict which men's cancer won't respond to certain hormone therapy, so they can pick the treatment that works for them while saving the NHS potentially huge sums on otherwise wasted drugs.
When the Sunday Mirror's editor, Gary Jones, fell ill after a holiday in Spain, it led to a shock diagnosis and urgent surgery to remove his prostate. He recalls the rollercoaster of emotions he experienced since then and explains why his life will never be the same again.
We handed in our ‘Don’t delay funding for vital new drugs and treatments’ petition to NHS England, to urge them to reconsider plans for a new spending cap on treatments. We received an incredible 29,006 signatures, but unfortunately the outcome wasn’t what we hoped for.
For many men, the side effects of prostate cancer treatment can be as daunting as the disease itself. Wildlife photographer Gary tells us how the shock of his diagnosis was compounded by fears of incontinence after having surgery, and what he did to give himself the best chance of preventing it.
Thousands of men could be delayed or denied life-saving new drugs under plans to cap spending by NHS England, prompting "serious concern" and an online petition from leading health and care charities.
BLOG: It's been 12 months since we launched our ambitious plan to halve prostate cancer deaths in a decade, and we’ve already taken some huge steps towards our goal. Our chief executive, Angela Culhane, reflects on the progress we’ve made and the exciting work still to come.
BLOG: Today, Prostate Cancer UK and 67 other charities signed a joint letter to the Prime Minister, urging the government to use the Spring Budget to give the NHS the money it needs to end the current crisis. Our Change Delivery Manager, Martin Abrams, explains why the NHS's whole future is at stake.
After today's confirmation that mpMRI scans before a biopsy can radically improve the accuracy of prostate cancer diagnosis, figures reveal that just 32% of eligible men currently have access to the procedure because of a shortage of scanners and qualified staff to use them in the NHS.
Today's Scottish green light for the chemotherapy drug means the same key treatments for advanced prostate cancer are now routinely available to eligible men in all the home nations.